Description
Beiersdorf: Initiation Of Coverage- Igniting Growth With Bold Skincare & Deodorant Product Launches!
Beiersdorf AG’s performance for the first half of 2025 reflects mixed results amid challenging market conditions, highlighting both positives and negatives that may influence investor considerations. Positively, Beiersdorf’s overall group organic sales grew by 2.1%, supported by its Consumer and tesa business segments. The Derma business, in particular, continued its robust growth trajectory, achieving double-digit organic sales growth of 12.2%, driven by innovation and expansion into white spaces. The Eucerin brand, part of the Derma segment, showcased exceptional performance with the successful launch of its Epicelline product, capturing significant market shares in several countries and establishing a strong consumer base. Furthermore, the Health Care business, which includes brands like Hansaplast and Elastoplast, reported commendable growth of 8.4%, boosted by new product innovations.
Our Report Structure:
⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures
Want unlimited access to our reports? Purchase our $99 annual subscription!